A Phase 1 interventional study of Selpercatinib in Healthy and Renal Insufficiency, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Renal Insufficiency by Eli Lilly and Company — 1 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Eli Lilly and Company.
Among the 12 studies in Renal Insufficiency by Eli Lilly and Company, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 12 in phase 1, and was the 3rd registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →1 of the 12 studies in Renal Insufficiency by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company · Sites in United States
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 30 across the 12 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
1 of the studies in Renal Insufficiency by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07924930Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyA Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney Function | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Renal Insufficiency by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 9 days, excluding screening.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For all participants:
For renal participants:
Baseline estimated (eGFR) based on the Modification of Diet in Renal Disease (MDRD) equation at screening as follows:
The MDRD equation is as follows (for females multiply result by 0.742, if African American multiply result by 1.212):
eGFR = 175 x [serum creatinine in milligrams per deciliter (mg/dL) measured with a standardized assay]\^-1.154 x (Age)\^-0.203
Exclusion Criteria:
For renal participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal renal function (estimated glomerular filtration rate greater than or equal to \[eGFR ≥ 90 milliliters per minute (mL/min) per 1.73 square meters (m²)\] received a single 160 milligrams (mg) oral dose of Selpercatinib on Day 1, administered in a fasted state.
Drug: Selpercatinib
Participants with mild renal impairment (eGFR between 60 and 90 mL/min/1.73 m²) received a single 160 mg oral dose of Selpercatinib on Day 1, administered in a fasted state.
Drug: Selpercatinib
Participants with moderate renal impairment (eGFR between 30 and 60 mL/min/1.73 m²) received a single 160 mg oral dose of Selpercatinib on Day 1, administered in a fasted state.
Drug: Selpercatinib
Participants with severe renal impairment (eGFR less than (\<) 30 mL/min/1.73 m² and not requiring hemodialysis) received a single 160 mg oral dose of Selpercatinib on Day 1, administered in a fasted state.
Drug: Selpercatinib
Administered orally
Also known as: LY3527723, LOXO-292
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib in Plasma
PK: AUC0-t of Selpercatinib
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma
PK: AUC0-inf of Selpercatinib
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib.in Plasma
PK: Percentage of AUC0-inf extrapolated was calculated as (1 - AUC0-t/AUC0-inf) \* 100.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma
PK: Cmax of Selpercatinib
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Selpercatinib in Plasma
PK: Tmax of Selpercatinib
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib in Plasma
PK: Apparent terminal elimination rate constant; represents the fraction of drug eliminated per unit time calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma
PK: t½ of Selpercatinib.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib in Plasma
PK: CL/F of Selpercatinib
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent Volume of Distribution During the Terminal Elimination Phase After Oral (Extravascular) Administration (Vz/F) of Selpercatinib in Plasma
PK: Vz/F of Selpercatinib
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Unbound AUC0-t (AUC0-t,u) of Selpercatinib in Plasma
AUC0-t,u was calculated by multiplying AUC0-t by Fu (i.e., AUC0-t\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Unbound AUC0-inf (AUC0-inf,u) of Selpercatinib in Plasma
AUC0-inf,u was calculated by multiplying AUC0-inf by Fu (i.e., AUC0-inf\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Unbound Cmax (Cmax,u) of Selpercatinib in Plasma
Cmax,u was calculated by multiplying Cmax by Fu (i.e., Cmax\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Unbound CL/F (CL/F,u) of Selpercatinib in Plasma
CL/F,u was calculated by multiplying CL/F by Fu (i.e., CL/F\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Unbound Vz/F (Vz/F,u) of Selpercatinib in Plasma
Vz/F,u was calculated by multiplying Vz/F by Fu (i.e., Vz/F\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Cumulative Amount of Selpercatinib Excreted (CumAe) in Urine
PK: CumAe was reported. The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.
Time frame: Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose
PK: Cumulative Percentage of Administered Selpercatinib Dose (Cum%Dose) Excreted in Urine
PK: Cum%Dose was reported. The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.
Time frame: Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose
PK: Renal Clearance (CLr) of Selpercatinib in Urine
PK: CLr of Selpercatinib was reported.The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.
Time frame: Predose (spot collection), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours postdose
| Milestone | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| Started | 13 | 9 | 8 | 7 |
| Received at least one dose of selpercatinib | 13 | 9 | 8 | 7 |
| Completed | 13 | 9 | 8 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
PK: AUC0-t of Selpercatinib
| nanogram*hour per milliliter (ng*hr/mL) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib in Plasma | 19770 ± 52.1 | 23440 ± 36.0 | 29270 ± 25.6 | 20640 ± 71.0 |
PK: AUC0-inf of Selpercatinib
| nanogram*hour per milliliter (ng*hr/mL) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma | 19870 ± 52.0 | 23510 ± 36.0 | 29470 ± 25.8 | 21000 ± 71.4 |
PK: Percentage of AUC0-inf extrapolated was calculated as (1 - AUC0-t/AUC0-inf) \* 100.
| percentage of AUCextrap | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib.in Plasma | 0.4856 ± 0.12819 | 0.2988 ± 0.10713 | 0.6738 ± 0.33398 | 1.706 ± 1.5917 |
PK: Cmax of Selpercatinib
| nanogram per milliliter (ng/mL) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma | 1399 ± 107.3 | 2247 ± 22.3 | 1742 ± 25.1 | 1006 ± 159.6 |
PK: Tmax of Selpercatinib
| hours (hr) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Time to Maximum Observed Plasma Concentration (Tmax) of Selpercatinib in Plasma | 1.500 (1.00 to 24.00) | 1.500 (1.50 to 2.00) | 1.500 (1.00 to 3.00) | 1.000 (0.50 to 24.00) |
PK: Apparent terminal elimination rate constant; represents the fraction of drug eliminated per unit time calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).
| One per hour (1/hour) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib in Plasma | 0.02853 ± 0.0043443 | 0.03434 ± 0.012429 | 0.02662 ± 0.0047866 | 0.02204 ± 0.0061504 |
PK: t½ of Selpercatinib.
| hours (hr) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma | 24.854 ± 4.0850 | 22.632 ± 8.7328 | 27.139 ± 7.1091 | 33.828 ± 10.4879 |
PK: CL/F of Selpercatinib
| Liters per Hour (L/h) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib in Plasma | 8.976 ± 4.6533 | 7.188 ± 2.6117 | 5.581 ± 1.3807 | 9.184 ± 6.5822 |
PK: Vz/F of Selpercatinib
| Liter | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Apparent Volume of Distribution During the Terminal Elimination Phase After Oral (Extravascular) Administration (Vz/F) of Selpercatinib in Plasma | 334.5 ± 225.17 | 227.9 ± 106.14 | 219.4 ± 82.255 | 444.7 ± 309.92 |
AUC0-t,u was calculated by multiplying AUC0-t by Fu (i.e., AUC0-t\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
| nanogram*hour per milliliter (ng*hr/mL) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Unbound AUC0-t (AUC0-t,u) of Selpercatinib in Plasma | 533.1 ± 54.3 | 659.7 ± 24.4 | 856.3 ± 28.0 | 709.9 ± 93.0 |
AUC0-inf,u was calculated by multiplying AUC0-inf by Fu (i.e., AUC0-inf\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
| nanogram*hour per milliliter (ng*hr/mL) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Unbound AUC0-inf (AUC0-inf,u) of Selpercatinib in Plasma | 535.7 ± 54.3 | 661.6 ± 24.4 | 862.1 ± 28.1 | 722.3 ± 93.9 |
Cmax,u was calculated by multiplying Cmax by Fu (i.e., Cmax\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
| nanogram per milliliter (ng/mL) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Unbound Cmax (Cmax,u) of Selpercatinib in Plasma | 37.72 ± 113.6 | 63.23 ± 23.4 | 50.95 ± 28.5 | 34.60 ± 187.8 |
CL/F,u was calculated by multiplying CL/F by Fu (i.e., CL/F\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
| Liters per Hour (L/h) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Unbound CL/F (CL/F,u) of Selpercatinib in Plasma | 337.9 ± 194.45 | 247.9 ± 58.030 | 191.6 ± 49.277 | 300.6 ± 294.31 |
Vz/F,u was calculated by multiplying Vz/F by Fu (i.e., Vz/F\*Fu). Fu represented the unbound fraction of Selpercatinib in plasma, that is, the portion of the drug not bound to plasma proteins.
| Liter (L) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Unbound Vz/F (Vz/F,u) of Selpercatinib in Plasma | 12700 ± 9498.5 | 8214 ± 4487.5 | 7697 ± 3676.1 | 14340 ± 12842 |
PK: CumAe was reported. The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.
| milligram (mg) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Cumulative Amount of Selpercatinib Excreted (CumAe) in Urine | 16.14 ± 9.5297 | 14.54 ± 3.1611 | 13.94 ± 5.3203 | 7.652 ± 5.4210 |
PK: Cum%Dose was reported. The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.
| percentage of dose excreted | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Cumulative Percentage of Administered Selpercatinib Dose (Cum%Dose) Excreted in Urine | 10.09 ± 5.9560 | 9.087 ± 1.9757 | 8.713 ± 3.3252 | 4.782 ± 3.3881 |
PK: CLr of Selpercatinib was reported.The urine sampling time points from pre-dose through 168 hours post-dose were used to assess this outcome.
| milliliter per hour (mL/hr) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| PK: Renal Clearance (CLr) of Selpercatinib in Urine | 735.9 ± 230.39 | 641.6 ± 243.96 | 480.4 ± 208.23 | 314.6 ± 94.084 |
Collected over Baseline up to 15 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selpercatinib (Control; Normal Renal Function) | 0/13 (0%) | 0/13 (0%) | 2/13 (15.4%) |
| Selpercatinib (Mild Renal Impairment) | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Selpercatinib (Moderate Renal Impairment) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Selpercatinib (Severe Renal Impairment) | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Event | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/13 | 0/9 | 2/8 | 0/7 |
| NauseaGastrointestinal disorders | 0/13 | 2/9 | 0/8 | 0/7 |
| SomnolenceNervous system disorders | 0/13 | 2/9 | 1/8 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 1/13 | 0/9 | 0/8 | 1/7 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/13 | 0/9 | 0/8 | 1/7 |
| DizzinessNervous system disorders | 0/13 | 0/9 | 0/8 | 1/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/13 | 0/9 | 0/8 | 1/7 |
| Abdominal distensionGastrointestinal disorders | 0/13 | 1/9 | 0/8 | 0/7 |
| ConstipationGastrointestinal disorders | 1/13 | 1/9 | 0/8 | 0/7 |
| Dry mouthGastrointestinal disorders | 0/13 | 1/9 | 0/8 | 0/7 |
All enrolled participants.
| Age, Continuous(years) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) | Total |
|---|---|---|---|---|---|
| Mean | 59.40 ± 6.42 | 58.40 ± 6.23 | 62.60 ± 6.02 | 61.30 ± 5.85 | 60.20 ± 6.14 |
| Sex: Female, Male(Participants) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) | Total |
|---|---|---|---|---|---|
| Female | 6 | 3 | 2 | 2 | 13 |
| Male | 7 | 6 | 6 | 5 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 1 | 3 | 11 |
| Not Hispanic or Latino | 9 | 6 | 7 | 4 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 3 | 4 | 2 | 16 |
| White | 6 | 6 | 4 | 5 | 21 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Selpercatinib (Control; Normal Renal Function) | Selpercatinib (Mild Renal Impairment) | Selpercatinib (Moderate Renal Impairment) | Selpercatinib (Severe Renal Impairment) | Total |
|---|---|---|---|---|---|
| United States | 13 | 9 | 8 | 7 | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Aug 2019, 7 months.
Results were first posted in Sep 2025, 6 years 1 month after primary completion.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib